Sorafenib Tosylate, also known as Bay 43-9006, is a novel bi-aryl urea compound that inhibits cell proliferation by targeting receptor tyrosine kinases, including VEGFR-2 and PDGFR-β and their associated signaling cascades of the ERK pathway and angiogenesis. It was originally developed as a Raf kinase inhibitor. It has been shown to have activity against several receptor tyrosine kinases involved in tumorigenesis and angiogenesis. Sorafenib is not active against erbB1, erbB2, ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-MET, c-yes, PKB, PKA, cdk1/cyclinB, PKC, or pim-1. Sorafenib has been shown to inhibit various nonkinase targets, including adenosine A3, dopamine D1, and muscarine M3 receptors, but at much higher (micromolar) concentrations than kinase targets. It is also the active ingredient in a drug that has been approved in at least one country for use in patients with advanced renal cell cancer. This version is NOT for human use.

Sorafenib Tosylate, Bay 43-9006

≥99% by HPLC

Sorafenib inhibits a number of kinases with the following IC50 values: Raf-1 (6 nM), BRAF (22 nM), VEGFR2 (90 nM), Flt-3 (58 nM, cKit (68 nM), and FGFR-1 (580 nM).

Soluble in DMSO at 200 mg/ml. It is poorly soluble in ethanol and water. The maximum solubility in plain water is ~10-20 µM.

A crystalline solid.

Store at or below –20°C. Solid form is stable at least 12 months from date of receipt, when stored as directed. Do not store aqueous solutions for more than one day.

1. Wilhelm, S.M., et al., Cancer Res. 2004;64:7099-7109.
2. Carter, C., et al., "Investigators Brochure Bay 43-9006/ Raf Kinase Inhibitor." Version No. 5. West Haven, CT, Bayer Pharmaceuticals Corporation, 2004.

Kinase

Inhibitor